Lyell Immunopharma, Inc.

LYEL

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001806952

D

fourth fifth of 369 graded peers in healthcare

rank 248 of 369; percentile 67.1; sampling error 2.5 points; lower is stronger

A B C D E

D, the sloth



Scoreboard

Profitability	A percentile 14.0
Solvency	C percentile 57.1
Growth and financing	E percentile 89.9
Reliability	0.87 AUC filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$120M to $591M assets total assets $340.1M
Standard universe	outside revenue above $1M and assets above $10M
Warnings	dilution, degenerate inputs not computable: fortress balance sheet
Inputs computable	7 of 14
Graded from	filings received through Mar 12, 2026 237 days before the rescan; latest periodic filing 10-Q received Aug 6, 2026
Last close	$10.76 2026-11-03; market equity $263.7M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 12, 2026

We are a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with cancer. Our goal is to fully realize the curative potential of cell therapy for patients with hematologic malignancies and solid tumors. To achieve this, we are pioneering novel approaches designed to generate T?cell therapies that drive long-lasting clinical responses. Our CAR T-cell product candidates start with the identification of promising cancer targets.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 14.0						
Gross profitability	not computable	32.4%				
one or more required annual facts are missing						
Return on invested capital	not computable	9.3%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

one or more required annual facts are missing						
Accruals ratio	(29.9%)	(6.6%)		14.0	803	2025-12-31
Gross margin stability, five years	not computable	2.8 pts				
five annual gross margins are required; found 0						
Solvency, sleeve percentile 57.1						
Twelve-month failure probability	0.23%	0.08%		69.1	247	2026-06-30
Altman Z double-prime	(13.93)	(0.35)		68.2	747	2025-12-31
Net debt to EBITDA	not computable	1.82x				
one or more required annual facts are missing						
Interest coverage	not computable	(4.51x)				
one or more required annual facts are missing						
Current ratio	5.28x	2.92x		33.9	828	2025-12-31
Growth and financing, sleeve percentile 89.9						
Revenue growth, three-year compound	(92.5%)	10.1%		100.0	412	2025-12-31
Free cash flow growth, three-year compound	not computable	10.9%				
current FCF must be positive and base FCF must exceed $100,000						
Reinvestment rate	not computable	37.1%				
one or more required annual facts are missing						
Asset growth, three years	(28.7%)	2.2%		92.0	697	2025-12-31
Net share issuance, one year	57.9%	2.5%		77.8	632	2026-03-09

Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 57.9%
Degenerate inputs	latest revenue or assets are at or below the $100,000 validity floor

Among 369 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
243	Angiodynamics Inc. (ANGO)	65.8	D	fortress balance sheet
244	Exagen Inc. (XGN)	66.0	D	dilution, fortress balance sheet
245	Cardiff Oncology, Inc. (CRDF)	66.3	D	short runway, fortress balance sheet
246	Amylyx Pharmaceuticals, Inc. (AMLX)	66.6	D	short runway, degenerate inputs
247	InspireMD, Inc. (NSPR)	66.8	D	dilution, short runway, distress
248	Lyell Immunopharma, Inc. (LYEL)	67.1	D	dilution, degenerate inputs
249	PTC Therapeutics, Inc. (PTCT)	67.4	D	
250	Alpha Teknova, Inc. (TKNO)	67.7	D	
251	U S Physical Therapy Inc. (USPH)	67.9	D	
252	American Shared Hospital Services (AMS)	68.2	D	late filer
253	Iovance Biotherapeutics, Inc. (IOVA)	68.5	D	dilution, short runway

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

What the price implies

at the 2026-11-03 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(41.2%)	(2.2%)	21
Distance from 52-week high	(72.1%)	(29.8%)	12
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	(57.1%)	(0.9%)	12
Book value to price	0.89	0.28	83
Sales to price	0.00	0.30	1
Composite equity issuance, five years	not computable	20.5%	
Relative strength against the sector, log excess return	(0.70)	(0.19)	21

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$73.0M
Operating cash flow, four quarters	-$133.3M
Months of runway	6.6
Days since last periodic filing	90 (10-Q received Aug 6, 2026)
Median daily dollar volume, 63 sessions	$1.4M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$274.4M	2025-12-31	2026-03-12	10-K	26-017253
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$150.0M	2025-12-31	2026-03-12	10-K	26-017253
3	assets	us-gaap:Assets	$340.1M	2025-12-31	2026-03-12	10-K	26-017253
4	assets	us-gaap:Assets	$490.9M	2024-12-31	2026-03-12	10-K	26-017253
5	current assets	us-gaap:AssetsCurrent	$260.9M	2025-12-31	2026-03-12	10-K	26-017253
6	current liabilities	us-gaap:LiabilitiesCurrent	$49.4M	2025-12-31	2026-03-12	10-K	26-017253
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$1.6B	2025-12-31	2026-03-12	10-K	26-017253
8	operating income	us-gaap:OperatingIncomeLoss	-$269.4M	2025-12-31	2026-03-12	10-K	26-017253
9	book equity	us-gaap:StockholdersEquity	$248.2M	2025-12-31	2026-03-12	10-K	26-017253
10	liabilities	us-gaap:Liabilities	$91.8M	2025-12-31	2026-03-12	10-K	26-017253
11	revenue	us-gaap:Revenues	$36,000	2025-12-31	2026-03-12	10-K	26-017253
12	revenue	us-gaap:Revenues	$61,000	2024-12-31	2026-03-12	10-K	26-017253
13	revenue	us-gaap:Revenues	$130,000	2023-12-31	2026-03-12	10-K	26-017253
14	revenue	us-gaap:Revenues	$84.7M	2022-12-31	2025-03-11	10-K	25-011978
15	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$780,000	2025-12-31	2026-03-12	10-K	26-017253
16	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$162.4M	2024-12-31	2026-03-12	10-K	26-017253
17	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$464,000	2024-12-31	2026-03-12	10-K	26-017253
18	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$163.7M	2023-12-31	2026-03-12	10-K	26-017253

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

19	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$2.7M	2023-12-31	2026-03-12	10-K	26-017253
20	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$169.6M	2022-12-31	2025-03-11	10-K	25-011978
21	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$24.3M	2022-12-31	2025-03-11	10-K	25-011978
22	assets	us-gaap:Assets	$750.0M	2023-12-31	2025-03-11	10-K	25-011978
23	assets	us-gaap:Assets	$937.6M	2022-12-31	2024-02-28	10-K	24-007592
24	shares outstanding	dei:EntityCommonStockSharesOutstanding	23,307,143	2026-03-09	2026-03-12	10-K	26-017253
25	shares outstanding	dei:EntityCommonStockSharesOutstanding	295,228,868	2025-03-06	2025-03-11	10-K	25-011978

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.